Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme

Molecular Therapy

Volumn 17, Issue 12, 2009, Pages 2000-2009

  Meza, Nestor W ^a,b   Alonso Ferrero, Maria E ^a   Navarro, Susana ^a   Quintana Bustamante, Oscar ^a   Valeri, Antonio ^a   Garcia Gomez, Maria ^a   Bueren, Juan A ^a   Bautista, Jose M ^c   Segovia, Jose C ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSIDAD DE LOS ANDES   (Venezuela)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ISOENZYME; PYRUVATE KINASE; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; EMBRYO; ENGRAFTMENT; ENZYME DEFICIENCY; ERYTHROCYTE COUNT; ERYTHROCYTE DISORDER; GENE EXPRESSION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IN UTERO STEM CELL TRANSPLANTATION; MALE; MOUSE; MYELOABLATIVE CONDITIONING; NONHUMAN; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; PHENOTYPE; RETICULOCYTE; VIRAL GENE DELIVERY SYSTEM;

MUS;

EID: 73849125332     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.200     Document Type: Article

References (46)

1. Fothergill-Gilmore, LA and Michels, PA (1993). Evolution of glycolysis. Prog Biophys Mol Biol 59: 105-235.
2. Takenaka, M, Noguchi, T, Sadahiro, S, Hirai, H, Yamada, K, Matsuda, T et al. (1991). Isolation and characterization of the human pyruvate kinase M gene. Eur J Biochem 198: 101-106.
3. Miwa, S, Kanno, H and Fujii, H (1993). Concise review: pyruvate kinase defciency: historical perspective and recent progress of molecular genetics. Am J Hematol 42: 31-35.
4. Kanno, H, Fujii, H, Tsujino, G and Miwa, S (1993). Molecular basis of impaired pyruvate kinase isozyme conversion in erythroid cells: a single amino acid substitution near the active site and decreased mRNA content of the R-type PK. Biochem Biophys Res Commun 192: 46-52.
5. Tanaka, KR and Zerez, CR (1990). Red cell enzymopathies of the glycolytic pathway. Semin Hematol 27: 165-185.
6. Bianchi, P and Zanella, A (2000). Hematologically important mutations: red cell pyruvate kinase (Third update). Blood Cells Mol Dis 26: 47-53.
7. Lenzner, C, Nürnberg, P, Jacobasch, G, Gerth, C and Thiele, BJ (1997). Molecular analysis of 29 pyruvate kinase-defcient patients from central Europe with hereditary hemolytic anemia. Blood 89: 1793-1799.
8. Kanno, H, Fujii, H, Wei, DC, Chan, LC, Hirono, A, Tsukimoto, I et al. (1997). Frame shift mutation, exon skipping, and a two-codon deletion caused by splice site mutations account for pyruvate kinase defciency. Blood 89: 4213-4218.
9. van Wijk, R, van Solinge, WW, Nerlov, C, Beutler, E, Gelbart, T, Rijksen, G et al. (2003). Disruption of a novel regulatory element in the erythroid-specific promoter of the human PKLR gene causes severe pyruvate kinase defciency. Blood 101: 1596-1602.
10. Diez, A, Gilsanz, F, Martinez, J, Pérez-Benavente, S, Meza, NW and Bautista, JM (2005). Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression. Blood 106: 1851-1856.
11. Beutler, E and Gelbart, T (2000). Estimating the prevalence of pyruvate kinase defciency from the gene frequency in the general white population. Blood 95: 3585-3588.
12. Miwa, S and Fujii, H (1996). Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes. Am J Hematol 51: 122-132.
13. Cazzola, M (2005). Pyruvate kinase defciency. Haematologica 90: 1-2.
14. Tanphaichitr, VS, Suvatte, V, Issaragrisil, S, Mahasandana, C, Veerakul, G, Chongkolwatana, V et al. (2000). Successful bone marrow transplantation in a child with red blood cell pyruvate kinase defciency. Bone Marrow Transplant 26: 689-690.
15. Zaucha, JA, Yu, C, Lothrop, CD, Nash, RA, Sale, G, Georges, G et al. (2001). Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation. Biol Blood Marrow Transplant 7: 14-24.
16. Min-Oo, G, Fortin, A, Tam, MF, Nantel, A, Stevenson, MM and Gros, P (2003). Pyruvate kinase defciency in mice protects against malaria. Nat Genet 35: 357-362.
17. Morimoto, M, Kanno, H, Asai, H, Tsujimura, T, Fujii, H, Moriyama, Y et al. (1995). Pyruvate kinase defciency of mice associated with nonspherocytic hemolytic anemia and cure of the anemia by marrow transplantation without host irradiation. Blood 86: 4323-4330.
18. Richard, RE, Weinreich, M, Chang, KH, Ieremia, J, Stevenson, MM and Blau, CA (2004). Modulating erythrocyte chimerism in a mouse model of pyruvate kinase defciency. Blood 103: 4432-4439.
19. Kanno, H, Utsugisawa, T, Aizawa, S, Koizumi, T, Aisaki, K, Hamada, T et al. (2007). Transgenic rescue of hemolytic anemia due to red blood cell pyruvate kinase defciency. Haematologica 92: 731-737.
20. Tani, K, Yoshikubo, T, Ikebuchi, K, Takahashi, K, Tsuchiya, T, Takahashi, S et al. (1994). Retrovirus-mediated gene transfer of human pyruvate kinase (PK) cDNA into murine hematopoietic cells: implications for gene therapy of human PK defciency. Blood 83: 2305-2310.
21. Klein, C and Baum, C (2004). Gene therapy for inherited disorders of haematopoietic cells. Hematol J 5: 103-111.
22. Wang, C, Chiarelli, LR, Bianchi, P, Abraham, DJ, Galizzi, A, Mattevi, A et al. (2001). Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. Blood 98: 3113-3120.
23. Meza, NW, Quintana-Bustamante, O, Puyet, A, Rio, P, Navarro, S, Diez, A et al. (2007). In vitro and in vivo expression of human erythrocyte pyruvate kinase in erythroid cells: a gene therapy approach. Hum Gene Ther 18: 502-514.
24. Steiner, LA and Gallagher, PG (2007). Erythrocyte disorders in the perinatal period. Semin Perinatol 31: 254-261.
25. Surbek, D, Schoeberlein, A and Wagner, A (2008). Perinatal stem-cell and gene therapy for hemoglobinopathies. Semin Fetal Neonatal Med 13: 282-290.
26. Rio, P, Martinez-Palacio, J, Ramirez, A, Bueren, JA and Segovia, JC (2005). Effcient engraftment of in utero transplanted mice with retrovirally transduced hematopoietic stem cells. Gene Ther 12: 358-363.
27. Beauchemin, H, Blouin, MJ and Trudel, M (2004). Differential regulatory and compensatory responses in hematopoiesis/erythropoiesis in alpha-and beta-globin hemizygous mice. J Biol Chem 279: 19471-19480.
28. Persons, DA and Tisdale, JF (2004). Gene therapy for the hemoglobin disorders. Semin Hematol 41: 279-286.
29. Gilsanz, F, Vega, MA, Gómez-Castillo, E, Ruiz-Balda, JA and Omeñaca, F (1993). Fetal anaemia due to pyruvate kinase defciency. Arch Dis Child 69(5 Spec No): 523-524.
30. Wood, T (1968). The inhibition of pyruvate kinase by ATP. Biochem Biophys Res Commun 31: 779-785.
31. Xu, J, Christian, B and Jump, DB (2006). Regulation of rat hepatic L-pyruvate kinase promoter composition and activity by glucose, n-3 polyunsaturated fatty acids, and peroxisome proliferator-activated receptor-alpha agonist. J Biol Chem 281: 18351-18362.
32. Miwa, S, Kanno, H, Hirono, A and Fujii, H (1995). Red cell enzymopathies as a model of inborn errors of metabolism. Southeast Asian J Trop Med Public Health 26 Suppl 1: 112-119.
33. Murotsuki, J, Uehara, S, Okamura, K, Yajima, A, Oura, T and Miyabayashi, S (1994). Fetal liver biopsy for prenatal diagnosis of carbamoyl phosphate synthetase defciency. Am J Perinatol 11: 160-162.
34. Golbus, MS, Simpson, TJ, Koresawa, M, Appelman, Z and Alpers, CE (1988). The prenatal determination of glucose-6-phosphatase activity by fetal liver biopsy. Prenat Diagn 8: 401-404.
35. Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. (2009). Gene therapy for immunodefciency due to adenosine deaminase defciency. N Engl J Med 360: 447-458.
36. Kustikova, O, Fehse, B, Modlich, U, Yang, M, Düllmann, J, Kamino, K et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308: 1171-1174.
37. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
38. Laufs, S, Guenechea, G, Gonzalez-Murillo, A, Zsuzsanna Nagy, K, Luz Lozano, M, del Val, C et al. (2006). Lentiviral vector integration sites in human NOD/SCID repopulating cells. J Gene Med 8: 1197-1207.
39. Modlich, U, Bohne, J, Schmidt, M, von Kalle, C, Knoss, S, Schambach, A et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity 10.1182/blood-2005-08-024976. Blood 108: 2545-2553.
40. Richard, E, Mendez, M, Mazurier, F, Morel, C, Costet, P, Xia, P et al. (2001). Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol Ther 4: 331-338.
41. Almarza, E, Río, P, Meza, NW, Aldea, M, Agirre, X, Guenechea, G et al. (2007). Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: a weak and effcient promoter for gene therapy. Mol Ther 15: 1487-1494.
42. Hildinger, M, Abel, KL, Ostertag, W and Baum, C (1999). Design of 5' untranslated sequences in retroviral vectors developed for medical use. J Virol 73: 4083-4089.
43. Miwa, S, Fujii, H, Takegawa, S, Nakatsuji, T, Yamato, K, Ishida, Y et al. (1980). Seven pyruvate kinase variants characterized by the ICSH recommended methods. Br J Haematol 45: 575-583.
44. Navarro, S, Meza, NW, Quintana-Bustamante, O, Casado, JA, Jacome, A, McAllister, K et al. (2006). Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1. Mol Ther 14: 525-535.
45. Meza, NW, Puyet, A, Pérez-Benavente, S, Quintana-Bustamante, O, Diez, A, Bueren, JA et al. (2006). Functional analysis of gammaretroviral vector transduction by quantitative PCR. J Gene Med 8: 1097-1104.
46. Villella, AD, Yao, J, Getty, RR, Juliar, BE, Constantin, Y, Hartwell, JR, Cai, S, Sadat, MA, Cornetta, K, Williams, DA and Pollok, KE. (2005). Real-time PCR: an effective tool for measuring transduction effciency in human hematopoietic progenitor cells. Mol Ther 11: 483-491.